Rapid health technology assessment of zanubrutinib in the treatment of B cell lymphomas
OBJECTIVE To rapidly assess the efficacy,safety and cost-effectiveness of novel highly selective Bruton's tyrosine kinase(BTK)inhibitor zanubrutinib in the treatment of chronic lymphocytic leukemia(CLL),small lymphocytic lymphoma(SLL)and mantle cell lymphoma(MCL).METHODS Retrieved from PubMed,Cochrane Library,CNKI,Wanfang database,VIP,and health technology assessment(HTA)websites,systematic reviews/meta-analyses,randomized controlled trials(RCTs),pharmacoeconomic studies and HTA reports related to zanubrutinib were collected from the database/website establishment to July 2023.The literature was screened according to inclusion and exclusion criteria,and its quality was assessed by using relevant evaluation tools.Data extraction was presented by qualitative description.RESULTS A total of 5 literature were included,comprising of 3 RCTs and 2 cost-effectiveness analyses.In terms of efficacy,compared with the control group,zanubrutinib treatment resulted in significantly longer progression-free survival(P＜0.05)and a higher overall response rate(P＜0.05).However,there was no statistical significance in overall survival between 2 groups(P＞0.05).In terms of safety,zanubrutinib had lower incidence of cardiac adverse events,incidence of major bleeding events,and drug discontinuation rate due to adverse drug events,compared to first-generation BTK inhibitors ibrutinib;but the risk of bleeding events caused by zanubrutinib was still higher,compared to traditional chemoimmunotherapy(bendamotine+rituximab).In terms of cost-effectiveness,zanubrutinib was found to be cost-effective in the treatment of recurrent or refractory MCL,compared to ibrutinib.CONCLUSIONS Zanubrutinib demonstrates sound efficacy and safety in patients with CLL/SLL and MCL patients.Furthermore,it exhibits economic advantages for patients with relapsed or refractory MCL.
zanubrutinibrapid health technology assessmentchronic lymphocytic leukemiasmall lymphocytic lymphomamantle cell lymphoma
万方数据
维普
